DARA Biosciences (DARA) vs. Its Rivals Critical Analysis

DARA Biosciences (NASDAQ: DARA) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it contrast to its peers? We will compare DARA Biosciences to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, profitability, earnings, dividends and valuation.

Profitability

This table compares DARA Biosciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DARA Biosciences -228.42% -145.61% -100.38%
DARA Biosciences Competitors -1,590.82% -52.78% -30.90%

Valuation and Earnings

This table compares DARA Biosciences and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
DARA Biosciences N/A N/A -1.69
DARA Biosciences Competitors $3.02 billion $642.98 million -31.87

DARA Biosciences’ peers have higher revenue and earnings than DARA Biosciences. DARA Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and target prices for DARA Biosciences and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DARA Biosciences 0 0 0 0 N/A
DARA Biosciences Competitors 74 343 1002 29 2.68

As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 22.67%. Given DARA Biosciences’ peers higher probable upside, analysts clearly believe DARA Biosciences has less favorable growth aspects than its peers.

Institutional & Insider Ownership

65.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 11.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

DARA Biosciences has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, DARA Biosciences’ peers have a beta of 1.29, meaning that their average share price is 29% more volatile than the S&P 500.

Summary

DARA Biosciences peers beat DARA Biosciences on 7 of the 8 factors compared.

DARA Biosciences Company Profile

DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company’s primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.

Receive News & Ratings for DARA Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DARA Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply